跳转至内容
Merck
CN

主要文件

查看所有文档

EHU003961

MISSION® esiRNA

targeting human USP13

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.51
UNSPSC Code:
41105324
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

AGATCGCCTGATGAACCAATTGATAGACCCATCAGACATCGATGAGTCATCAGTGATGCAGCTGGCCGAGATGGGTTTCCCGCTGGAAGCATGTCGCAAGGCTGTGTACTTCACTGGAAATATGGGCGCCGAGGTGGCCTTCAACTGGATCATTGTTCACATGGAAGAGCCAGATTTTGCTGAGCCGCTGACCATGCCTGGTTATGGAGGGGCAGCTTCTGCTGGAGCCTCTGTTTTTGGTGCTTCTGGACTGGATAACCAACCTCCAGAGGAAATCGTAGCTATCATCACCTCCATGGGATTTCAGCGAAATCAGGCTATTCAGGCACTACGAGCAACGAATAATAACCTGGAAAGAGCACTGGATTGGATCTTTAGCCACCCTGAGTTTGAAGAAGACAGTGATTTTGTGATTGAGATGGAGAATAATGCCAATGCA

Ensembl | human accession no.

ENSG00000058056

NCBI accession no.

NM_003940

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... USP13(8975)

General description

MISSION® shRNA是核糖核酸内切酶制备的siRNA。它们是靶向相同mRNA序列的siRNA异质混合物。这些多重沉默触发（multiple silencing trigger）导致高度特异性的、有效的基因沉默。

如需其他详细信息并查看所有可用的esiRNA选项，请访问SigmaAldrich.com/esiRNA。

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
XZU
ZYU
PKU
SJU
QCS

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

MISSION esiRNA

Instructions

Yue Wu et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 114, 108831-108831 (2019-04-16)
USP13 is emerging as a potential target in cancer therapy. However, the effect of USP13 on tumor progression is controversial. Here we focused on non-small cell lung cancer (NSCLC), a common cancer with high mortality, and studied the role of
Yuning Liao et al.
Journal of experimental & clinical cancer research : CR, 38(1), 157-157 (2019-04-13)
Prostate cancer (PCa) remains a challenge worldwide. Due to the development of castration-resistance, traditional first-line androgen deprivation therapy (ADT) became powerlessness. Epidermal growth factor receptor (EGFR) is a well characterized therapeutic target to treat colorectal carcinoma and non-small cell lung
Shan Gao et al.
Frontiers in cell and developmental biology, 8, 587389-587389 (2020-11-17)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. The activation of the toll-like receptor 4/myeloid differentiation primary response gene 88/nuclear factor-κB (TLR4/MyD88/NF-κB) pathway contributes to the development and progression of HCC. The ubiquitin-proteasome system regulates
查看所有相关文献

全球贸易项目编号

货号GTIN
EHU003961-20UG04061831360493
EHU003961-50UG04061831370393